



HAL
open science

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.

François-Clément Bidard, Tanja Fehm, Michail Ignatiadis, Jeffrey B. Smerage, Catherine Alix-Panabières, Wolfgang Janni, Carlo Messina, Costanza Paoletti, Volkmar Müller, Daniel F. Hayes, et al.

► **To cite this version:**

François-Clément Bidard, Tanja Fehm, Michail Ignatiadis, Jeffrey B. Smerage, Catherine Alix-Panabières, et al.. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.. Cancer and Metastasis Reviews, 2012, epub ahead of print. 10.1007/s10555-012-9398-0 . inserm-00749450v1

HAL Id: inserm-00749450


<https://inserm.hal.science/inserm-00749450v1>

Submitted on 7 Nov 2012 (v1), last revised 27 Nov 2012 (v2)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

DETECT III



- Primary endpoint: PFS (superiority)
- 2nd endpoints: OS, overall response rate, clinical benefit rate, QoL, CTC dynamics, safety & tolerability of lapatinib compliance to the study protocol, assessment of pain intensity
- Patients with bone metastasis will also receive denosumab in both arms